A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-09-15
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-26 (study day 65); relationship: Y
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-23 (study day 154); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 270); relationship: Y
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-23 (study day 274); relationship: not assessed
Data queries
No data queries.